Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 11/20 | 0.50 |
| ▸ | BMPR1B | O00238 | 9/20 | 0.50 |
| ▸ | BMPR1A | P36894 | 8/20 | 0.50 |
| ▸ | ACVR1B | P36896 | 8/20 | 0.50 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.50 |
| ▸ | BMP4 | P12644 | 4/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988798 | 0.85 | KDR (0.60) | KDRACVR1BMPR1BBMPR1AACVR1B | |
| SCHEMBL19110498 | 0.82 | ACVR1 (0.59) | ACVR1BMPR1BBMPR1AACVR1BACVRL1 | |
| SCHEMBL24409693 | 0.82 | ACVR1 (0.70) | KDRACVR1BMPR1BBMPR1AACVR1B | |
| SCHEMBL17442217 | 0.82 | ACVR1 (0.72) | ACVR1BMPR1BBMPR1AACVR1BACVRL1 | |
| SCHEMBL23988686 | 0.81 | KDR (0.58) | KDRACVR1BMPR1BBMPR1AACVR1B | |
| SCHEMBL23988822 | 0.81 | ACVR1 (0.72) | KDRACVR1BMPR1BBMPR1AACVR1B | |
| SCHEMBL23989017 | 0.79 | BMP4 (0.60) | KDRACVR1BMPR1BBMPR1AACVR1B | |
| SCHEMBL23988918 | 0.79 | ACVR1 (0.69) | KDRACVR1BMPR1BBMPR1AACVR1B | |
| SCHEMBL23988800 | 0.77 | KDR (0.59) | KDRACVR1BMPR1BBMPR1AACVR1B | |
| SCHEMBL23988808 | 0.77 | KDR (0.58) | KDRACVR1BMPR1BBMPR1AACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222875-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |